Codexis Invests in CO2 Solution Inc.

    


    
</pre>
<p>REDWOOD CITY, Calif., <chron>Dec. 15</chron> /CNW/ -- Codexis, Inc. today announced that it acquired 10,000,000 common shares of CO2 Solution Inc. by way of private placement at a price of Cdn.<money>$0.20</money> per common share in reliance upon the "minimum amount investment" prospectus and registration exemptions contained in National Instrument 45-106.  Codexis holds 16.59% of CO2 Solution's issued and outstanding common shares as a result of the private placement.</p>
<p/>
<p>Codexis acquired the common shares for investment purposes.  Codexis will review its holdings of common shares from time to time and may acquire additional securities or dispose of securities of CO2 Solution, in either case, in the open market, by private agreement or otherwise, in accordance with applicable securities laws.  The shares issued to Codexis as part of this private placement are subject to a four-month statutory resale restriction.</p>
<p/>
<p>CO2 Solution has agreed to name an individual identified by Codexis to its Board of Directors.  The Codexis nominee will take the place of a current director, who will then sit as a board observer until the next annual general meeting.</p>
<p/>
<p>A copy of Codexis' early warning report relating to the private placement and prepared in accordance with National Instrument 62-103 will be filed on SEDAR at <a href="http://www.sedar.com">www.sedar.com</a> and may be obtained by contacting <person>Lyn Christenson</person>, <a href="mailto:[email protected]">[email protected]</a>, 650-421-8144 or Saskia Sidenfaden, <a href="mailto:[email protected]">[email protected]</a>, 212-827-3771.</p>
<pre>
    

    About Codexis
    
</pre>
<p>Codexis, Inc. is a clean technology company. The company is a leading provider of proprietary, optimized biocatalytic solutions that enable the manufacture of products cost-effectively, at commercial scale and with significantly reduced environmental impact relative to conventional manufacturing processes.  Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalytic solutions in other bioindustrial markets, including carbon management, water treatment and chemicals.</p>
<p/>
<p>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.</p>
<p/>
<p>CONTACT: <person>Lyn Christenson</person>, <a href="mailto:[email protected]">[email protected]</a>, 650-421-8144 or Saskia Sidenfaden, <a href="mailto:[email protected]">[email protected]</a>, 212-827-3771</p>
<pre>
    




    

For further information: Lyn Christenson of Codexis, Inc., [phone], [email protected], or Saskia Sidenfaden, [phone], [email protected], for Codexis, Inc. Web Site: http://www.codexis.com